주식/증권
📉 부정적
VERAXA Biotech (VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase
요약
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug conjugate and engineered-antibody technologies. The company entered the NASDAQ market in June 2026 following its completed bus...